LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

Kodu・Aktsiate loetelu・KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc

Avatud

SektorTervishoid

26.8 0.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.74

Max

26.8

Põhinäitajad
By Trading Economics
Sissetulek	55M -5.4M
Müük	-2.9M -1.4M
Aktsiakasum	0.94
Kasumimarginaal	376.718
Töötajad	275
EBITDA	-2.3M -61M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+8.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	21. mai 2026

Turustatistika
By TradingEconomics
Turukapital	870M 1.4B
Eelmine avamishind	26.69
Eelmine sulgemishind	26.8

Uudiste sentiment

By Acuity

21%

79%

46 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

12.19 / 12.825 Toetus ja vastupanu

KalVista Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. sept 2025, 17:27 UTC

Suurimad hinnamuutused turgudel

KalVista Pharmaceuticals Shares Drop After Notes Offering Prices

7. juuli 2025, 11:30 UTC

Suurimad hinnamuutused turgudel

KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

KalVista Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

8.97% tõus

12 kuu keskmine prognoos

Keskmine 29.17 USD 8.97%

Kõrge 35 USD

Madal 27 USD

Põhineb 8 Wall Streeti analüütiku instrumendi KalVista Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi KalVista Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

12.19 / 12.825Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

46 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.